Next Article in Journal
MicroRNA Regulation of Epigenetic Modifiers in Breast Cancer
Previous Article in Journal
Heightened JNK Activation and Reduced XIAP Levels Promote TRAIL and Sunitinib-Mediated Apoptosis in Colon Cancer Models
Article Menu

Export Article

Open AccessArticle

Elevated Lactate Dehydrogenase Has Prognostic Relevance in Treatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12

1
Institute of Hematology, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Roma, Italy
2
Departments of Leukemia, MD Anderson Cancer Centre, Houston, TX 77030, USA
3
Hematology and Clinical Immunology Unit, Department of Medicine, Università di Padova, 35122 Padova, Italy
4
Hematology Unit, IRCCS Ca’ Granda Policlinico-Università degli Studi, 55031 Milano, Italy
5
Division of Hematology, Ospedale San Bortolo di Vicenza, 36100 Vicenza, Italy
6
Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126 Torino, Italy
7
Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, 10126 Torino, Italy
8
Hematology section, Department of Medical Sciences, Azienda Ospedaliero Universitaria Arcispedale S. Anna, 44124 Ferrara, Italy
9
Hematology Unit, Azienda Ospedaliera Universitaria Senese, 53100 Siena, Italy
10
Hematology division, Policlinico Umberto I, Università Sapienza, 00161 Roma, Italy
11
Department of Hematology, Ospedale Niguarda, 20162 Milano, Italy
12
Biothecnology Research Unit, Azienda Ospedaliera di Cosenza, 87100 Cosenza, Italy
13
Department of Hematology-Oncology, Ospedale Pugliese-Ciacco, 88100 Catanzaro, Italy
14
Division of Hematology, Ospedale Belcolle, 01100 Viterbo, Italy
15
Hematology and Stem cell Transplantation Unit, IRCCS Centro di Riferimento Oncologico della Basilicata, 85028 Rionero in Vulture, Italy
16
Hematology and Stem Cell Transplantation Unit, Ospedale A. Businco, 09121 Cagliari, Italy
17
Department of Hematology, Azienda Ospedaliera Bianchi-Melacrino-Morelli, 89124 Reggio Calabria, Italy
18
Molecular Hematology, International Centre for Genetic Engineering and Biotechnology, 34149 Trieste, Italy
19
Institute of Hematology, Università Cattolica del Sacro Cuore, 00168 Roma, Italy
*
Author to whom correspondence should be addressed.
Cancers 2019, 11(7), 896; https://doi.org/10.3390/cancers11070896
Received: 30 May 2019 / Revised: 16 June 2019 / Accepted: 18 June 2019 / Published: 26 June 2019
(This article belongs to the Special Issue Chronic Lymphocytic Leukemia)
  |  
PDF [1704 KB, uploaded 1 July 2019]
  |     |  

Abstract

Chronic Lymphocytic Leukemia (CLL) patients with +12 have been reported to have specific clinical and biologic features. We performed an analysis of the association between demographic; clinical; laboratory; biologic features and outcome in CLL patients with +12 to identify parameters predictive of disease progression; time to treatment; and survival. The study included 487 treatment-naive CLL patients with +12 from 15 academic centers; diagnosed between January 2000 and July 2016; and 816 treatment-naïve patients with absence of Fluorescence In Situ Hybridization (FISH) abnormalities. A cohort of 250 patients with +12 CLL followed at a single US institution was used for external validation. In patients with +12; parameters associated with worse prognosis in the multivariate model were high Lactate DeHydrogenase (LDH) and β-2-microglobulin and unmutated immunoglobulin heavy-chain variable region gene (IGHV). CLL patients with +12 and high LDH levels showed a shorter Progression-Free-Survival (PFS) (30 months vs. 65 months; p < 0.001), Treatment-Free-Survival (TFS) (33 months vs. 69 months; p < 0.001), Overall Survival (OS) (131 months vs. 181 months; p < 0.001) and greater CLL-related mortality (29% vs. 11% at 10 years; p < 0.001) when compared with +12 CLL patients with normal LDH levels. The same differences were observed in the validation cohort. These data suggest that serum LDH levels can predict PFS; TFS; OS and CLL-specific survival in CLL patients with +12. View Full-Text
Keywords: CLL; trisomy 12; LDH; prognosis CLL; trisomy 12; LDH; prognosis
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material

SciFeed

Share & Cite This Article

MDPI and ACS Style

Autore, F.; Strati, P.; Innocenti, I.; Corrente, F.; Trentin, L.; Cortelezzi, A.; Visco, C.; Coscia, M.; Cuneo, A.; Gozzetti, A.; Mauro, F.R.; Frustaci, A.M.; Gentile, M.; Morabito, F.; Molica, S.; Falcucci, P.; D’Arena, G.; Murru, R.; Vincelli, D.; Efremov, D.G.; Ferretti, A.; Rigolin, G.M.; Vitale, C.; Tisi, M.C.; Reda, G.; Visentin, A.; Sica, S.; Foà, R.; Ferrajoli, A.; Laurenti, L. Elevated Lactate Dehydrogenase Has Prognostic Relevance in Treatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12. Cancers 2019, 11, 896.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top